Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-B49 pembrolizumab plus chemotherapy in HR-positive/HER2-negative metastatic breast cancer
2020-005407-38Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Pembrolizumab plus chemotherapy with Placebo plus chemotherapy (2 arms). Primary endpoints: Progression-free survival per RECIST 1.1 by blinded independent central review in participants with CPS >=10 and Progression-free survival per RECIST 1.1 by blinded independent central review in participants with CPS >=1. Started Mar 2021; status: active.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2020-005407-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005407-38.